Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE: Letrozole +/- Everolimus in Premenopausal HR+/HER2- Metastatic Breast Cancer
NCT02313051Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus in breast cancer (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression free survival. Status: unknown.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02313051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313051.